Tolemy Bio banked €1.4M in a Pre-Seed round led by Norrsken Evolve. The investment represents the first external capital for the London-based startup as it moves to digitise cellular spatial data.
The company develops a platform that maps the precise location and interaction of cells within tissue. By creating high-resolution digital representations of biological environments, Tolemy Bio enables researchers to observe how cells communicate and change in response to disease or treatment. This spatial biology approach helps drug developers identify why certain therapies fail in specific tissue microenvironments.
The capital is earmarked for further development of its mapping technology and expanding its technical team in the UK. The startup aims to move biological research away from bulk analysis—which averages data across many cells—toward a more granular understanding of individual cellular architecture.
As biotech investors increasingly shift toward "tech-bio" platforms, Tolemy Bio joins a growing cohort of British startups applying computational layers to traditional pathology to accelerate drug discovery.
Originally reported by Tech Funding News.